NeuroPointDX Announces Confirmation of First-Generation Autism Diagnostic Panel
NeuroPointDX has validated 12 metabolic subtypes of autism spectrum disorder. The diagnostic blood test for ASD will be available later this year.
CEO Elizabeth Donley says, “This is a historic moment, not just for Stemina and NeuroPointDX, but for our knowledge and understanding of autism.”
- Two years following a fecal transplant treatment, test subjects retained improvements in autism symptoms and gut he… https://t.co/fbm7fV32NY5 hours ago
- CEO Elizabeth Donley presented findings from CAMP at the National @TACAfoundation Autism Conference – East Coast. D… https://t.co/p54MQvZlAcyesterday
- Is it time to rethink #AutismAwarenessMonth? https://t.co/tKunyTlAyS #Autism #AutismAcceptanceyesterday